participating centers and the investigators). Eligible patients with a diagnosis of stable or unstable angina or non-ST-elevation myocardial infarction or silent ischemia were included if they were aged ≥18 years and volunteered for follow-up. Patients were eligible if they had atherosclerotic coronary artery disease, including native and de novo lesions with a diameter stenosis of minimally 50% of reference vessel diameters ranging from 2.25 to 4.0 mm by quantitative coronary angiogram (QCA) with objective evidence of ischemia. Patients with acute coronary syndrome <72 hours before admission or creatin kinase twice compared with the upper normal limit, previous brachytherapy or DES implantation in the target lesion, restenotic lesion, allergy to aspirin or thienopyridine, bypass graft lesions, true bifurcated lesions, severe renal insufficiency (creatinin clearance <30 mL/min), severe liver failure (glutamyl oxaloacetic transaminase and glutamyl pyruvic transaminase >3× the upper normal limit), or life expectancy <1 year because of other pathologies were excluded from the study. Patients were requested to receive clinical follow-up at 1, 9, 12 , and 24 months and angiographic follow-up at 9 months. Incidence of in-stent restenosis and late lumen loss at 9 months were verified by QCA. Intravascular ultrasound (IVUS) was performed at postprocedure and angiographic follow-up to verify incidence of LISA and neointimal hyperplasia area (NIHA) at 9 months. Patients were assigned to undergo percutaneous coronary intervention with either PF-PES or PB-PES. Randomization was performed using a predefined computer-generated tabulated random order, which ensured near-equal numbers in each of the 2 arms before the attempt of stent implantation. Patients who met all the inclusion criteria and none of the exclusion criteria were randomized in order that they qualified. Time zero was defined as the time of randomization. Patients were considered enrolled in the study and eligible for the final intention-to-treat analysis at the time of randomization. The same randomly assigned stent had to be implanted in all lesions in those patients who required stenting in multiple lesions, and the use of >1 stent per lesion was also allowed. A total of 5 academic institutions participated in this trial. This was an investigator-initiated trial with no official sponsor involved in the study. All centers submitted and received the approval of their medical ethics committee for the protocol and for the informed consent. The study was performed in compliance with the protocol, the Declaration of Helsinki, British Standard European Norm International Standardization Organization 14155 Part 1 and Part 2, and applicable local requirements. All patients provided written informed consent.
Study Procedures
At least 2 hours before percutaneous coronary intervention, patient received a loading dose of 600 mg clopidogrel and 325 mg aspirin.
Immediately after the decision to perform the intervention, patient was given 100 IU/kg intravenous unfractionated heparin. Device implantation was performed according to standard procedure techniques. If an additional stent was required to cover the lesion, additional stents had to be identical to the randomized treatment group. Procedure success was defined as a residual stenosis in stent <30% by QCA without stent edge dissection and Thrombolysis in Myocardial Infarction >2 coronary flow. Electrocardiograms and cardiac biomarkers were to be evaluated before and after the index procedure.
After the procedure, both aspirin 100 mg per day and clopidogrel 75 mg per day were prescribed for ≥6 months. Other medications included β-blockers, statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers according to clinical practice. Clinical information at 1, 9, 12, and 24 months was obtained by either a hospital visit or telephone contact with the patient or the referring physician. At 9 months, control angiography was mandated to assess the long-term angiographic results. If clinically warranted, revascularization was performed at the physician's discretion. Relevant data were collected and entered into a computer database https://www.ecapture.net/LISA/.
Study Devices
The PF-PES (Axxion) is a balloon-expandable, 316 L stainless steel stent with 117 μm strut thickness. The whole surface of the stent is coated with synthetic glycocalix, which is a permanent biocompatible carbohydrate of glycoproteins and glycolipid. This surface modification mimics naturally occurring endothelial surface glycocalix and acts as a hemocompatible protective barrier similar to that found on native endothelium, resulting in less inflammation, less immunologic responses, and prevention of thrombosis. 16 Paclitaxel, which inhibits smooth muscle cell proliferation and migration, secretion of extracellular matrix, and inflammation, is spray-coated onto the synthetic glycocalix substrate on the abluminal surface of stent only. The thickness of coating is ≈2 nm, and the dosage of drug is ≈2.7 μg/mm 2 . This process assures that the high concentration of paclitaxel is delivered directly to the vessel intima. Approximately 40% to 50% of drug is released within the first week, and the remainder is released in the next 3 weeks. 17 PB-PES (TAXUS Express) is a balloon-expandable, 316 L stainless steel stent with a permanent polymer. The strut thickness is 132 μm, and the thickness of coating is ≈16 μm. The coating is composed of 1 μg/mm 2 antiproliferative drug paclitaxel and a poly(styrene-bisobutylene-b-styrene), which provides controlled biphasic release. The first release of paclitaxel (≈38% of the 10-day dose) occurs during the first 48 hours after implantation, and in the second phase, paclitaxel is slowly released during the next 10 days. 18
Angiographic Analysis
QCA data were recorded into compact discs, and analysis was performed offline by an expert analyst in the independent core laboratory of the Hospital Clinic, blinded to the stent type, using automated edge-detection algorithms (CMS version 6.0; Medis Medical Imaging Systems, Nuenen, the Netherlands). Lesion complexity was analyzed according to the modified American Heart Association/American College of Cardiology grading classification. 19 In each lesion, the coronary segment, including the stent and 5 mm proximal and distal to the stent edge, was analyzed at baseline and at 9-month follow-up. Late loss was estimated as the difference between the minimal lumen diameter at postimplantation and at follow-up using matched angiographic views. The pattern of in-stent restenosis was classified on the basis of Mehran classification. 20 To evaluate intraobserver variability, the observer repeated the analysis 3 months later.
IVUS Analysis
IVUS imaging was obtained at poststenting and at 9-month follow-up and performed after 100 to 200 μg of intracoronary nitroglycerin injection using a motorized transducer pullback system and a commercial scanner that consisted of a rotating 40-MHz transducer within a 2.5F imaging sheath (Galaxy2; Boston Scientific Corporation). The ultrasound catheter was advanced ≤10 mm beyond the stent into the
WHAT IS KNOWN
• Many drug-eluting stents used commonly in clinical practice include a polymer as part of the drug delivery system.
• Polymer(s) may provoke a localized vascular hypersensitivity reaction that in select instances can promote stent thrombosis.
• To date, there have been no randomized trials comparing polymer-free paclitaxel-eluting stents (PES) with polymer-based PES.
WHAT THE STUDY ADDS
• Polymer-free PES was associated with increased neointimal hyperplasia and clinical restenosis as compared with a PES with a polymer delivery system.
• Polymer was determined to play an essential role in the performance of the PES. distal vessel, and the transducer was withdrawn at an automatic pullback speed of 0.5 mm/s to a point ≤10 mm proximal to the stent. All IVUS data were recorded on compact discs and analyzed by an expert analyst blinded to stent type in the independent core laboratory of the Hospital Clinic. Cross-sections at 1-mm intervals within the stent segment were analyzed. The external elastic membrane, lumen, and stent contours were detected using offline software (QCU version 2.0; Medis Medical Imaging Systems). Vessel area and lumen area were automatically drawn, and stent area was drawn at the endoluminal site of the metallic struts. Minor modifications were made whenever necessary. NIHA was calculated as difference between stent area and lumen area at follow-up. NIHA was normalized per stent size as %NIHA and calculated as (NIHA/stent area)×100. The peri-stent area was derived by (vessel area-stent area) and normalized per stent size as percent peri-stent area and calculated as (peri-stent area/vessel area)×100. Incomplete stent apposition was defined as a separation of at least a single stent strut from the intimal surface of the arterial wall. Incomplete stent apposition was classified into the following 3 groups on the basis of serial assessment 1 : resolved-incomplete stent apposition present after the procedure but no longer present at follow-up 2 ; persistent-incomplete stent apposition present both after the procedure and follow-up 3 ; and LISA not present at baseline but present at follow-up. [21] [22] [23] To evaluate intraobserver variability, the observer repeated the analysis 3 months later.
Study End Point
The primary end point of this study was late loss at 9 months by QCA. Regarding clinical end points, the efficacy end point was any target lesion revascularization at 2 years on patient basis, whereas the safety end point was a composite of all-cause death, any myocardial infarction, and target vessel revascularization (TVR) at 2 years. Target lesion revascularization was defined as either percutaneous coronary intervention or coronary artery bypass grafting owing to restenosis or other complication of the target lesion. All-cause death included noncardiac and cardiac death. Cardiac death was defined as any death because of cardiac cause (myocardial infarction, low-output failure, and fatal arrhythmia), death related to the procedure, or death of unknown cause. TVR was defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion. Stent thrombosis was assessed according to Academic Research Consortium criteria. 24 All adverse events were adjudicated by an event committee blinded to treatment allocation.
Statistical Analysis
Categorical variables were presented as numbers and percentages and compared between groups with χ 2 or Fisher exact tests, when appropriate. Continuous data were shown as mean±SD and compared using the Mann-Whitney test. Comparison of data at lesion level has been performed accounting for clustering within patient. 25 Intraobserver reproducibility of QCA and IVUS was calculated by intraclass correlation coefficient for repeated measurement. Survival and event-free status were assessed using the methods of Kaplan-Meier. A sample size of 105 patients per group was calculated with a statistical power of 90% and a 2-sided type 1 error of 0.05 to detect a difference in ). Expecting that ≈25% to 30% of the patients would have been lost at follow-up, a total of 270 patients were planned to be enrolled. A 2-sided P value <0.05 was considered statistically significant. All statistical analyses were performed using SPSS (version 11.0.1; SPSS Inc, Chicago, IL).
Results

Baseline Characteristics and Procedural Results
From October 2007 to April 2009, a total of 165 patients were enrolled into the trial. The trial was prematurely stopped because of higher-than-expected rate of events in PF-PES. Excluding 1 patient who withdrew consent, 164 patients with 206 lesions were randomly assigned to receive either PF-PES (84 patients with 101 lesions) or PB-PES (80 patients with 105 lesions; Figure 1 ). As shown in Tables 1 and 2, the 2 groups were well balanced in terms of baseline and procedural characteristics, with exception of significantly higher postprocedure percentage stenosis in PF-PES (12.26±6.80% versus 14.84±6.89%; P=0.002). All procedures were successfully performed.
Angiographic Outcomes at 9-Month Follow-Up
Among the enrolled 164 patients, follow-up angiogram was performed in only 134 patients (82%) at 288±89 days after index procedure, because of premature discontinuation of the trial. Eventually, 125 paired patients with 157 lesions were available for QCA analysis. The intraobserver reproducibility value of QCA continuous variables (intraclass correlation coefficient) was 0.900. Table 3 shows the angiographic results in patients whose angiographic data at both baseline and follow-up were available for analysis. Instent late loss was 0.90±0.59 mm for PF-PES and 0.49±0.52 mm for PB-PES (P<0.001). In-segment late loss and binary restenosis were also significantly higher in PF-PES (0.54±0.64 versus 0.22±0.45 mm; P=0.001, and 38% versus 9%; P<0.001; Figure 2 ). In particular, PF-PES exhibited a higher incidence of diffuse in-stent restenosis as compared with PB-PES.
IVUS Outcomes at 9-Month Follow-Up
Among the enrolled 164 patients, baseline IVUS was performed in 163 patients (99%), and follow-up IVUS was performed in 114 patients (70%). Eventually, 96 paired patients with 116 lesions were available for IVUS analysis. The intraobserver reproducibility value of IVUS continuous variable (intraclass correlation coefficient) was 0.957. Table 4 shows the IVUS results in patients whose IVUS data at both baseline and follow-up were available for analysis. Mean NIHA and %NIHA at 9-month follow-up were significantly higher in PF-PES than in PB-PES (1.42±1.09 versus 0.51±0.61 mm 2 ; P<0.001, and 19.02±14.32% versus 6.26±9.84%; P<0.001). Three cases of LISA were detected at 9 months. No significant difference was observed in the occurrence of LISA between 2 groups. higher rate of TVR (35.7% versus 13.8%; P=0.001; Figure 3 ; Table 5 ). No differences were observed between 2 groups in terms of all-cause death (1.3% versus 1.2%; P=1.000) and any myocardial infarction (1.3% versus 1.2%; P=1.000). Target lesion revascularization was 33.3% for PF-PES and 12.5% for PB-PES (P<0.001). One definite stent thrombosis was observed at 205 days in PF-PES.
Clinical Outcomes at 2-Year Follow-Up
Discussion
The main findings of this trial were the following: angiographic primary end point and IVUS data evaluated at 9 months were significantly higher by the use of PF-PES. These findings were translated into a higher clinical restenosis and subsequent cardiac events at 2 years.
Three randomized trials comparing previous generation of PF-PES and BMS have been published. ASPECT and ELUTES enrolled 177 and 192 patients, respectively, and randomized to receive either stainless steel stent or the same stent coated with paclitaxel at different doses. 9,10 A dose-dependent effect was observed in the angiographic pattern of neointimal formation; the highest dose density of paclitaxel in the 2 trials resulted in a significantly smaller late loss at followup in comparison with the control (ASPECT: 0.29±0.72 versus 1.04±0.83 mm; P<0.001; ELUTES: 0.11±0.50 versus 0.73±0.73 mm; P=0.002). Six-month binary restenosis of each PF-PES with the highest dose was 4.0% for ASPECT and 3.2% for ELUTES. 27 In contrast to these findings, the Drug Eluting Coronary Stent Systems in the Treatment of Patients with De Novo Native Coronary Lesions (DELIVER) trial, which enrolled 1043 patients and randomized to receive either stainless steel stent or the same stent coated with paclitaxel at a dose density of 3.0 μg/mm 2 , demonstrated no significant difference in terms of binary restenosis at 8 months (14.9% for PF-PES versus 20.6% for BMS; P=0.076) despite significant lower late loss of PF-PES than that of BMS (0.81±0.60 versus 0.98±0.57 mm; P=0.003). 11 Polymer has an important role in drug storage and control of elution kinetics, but it may also provoke hypersensitivity reactions with subsequent inflammatory responses potentially resulting in delayed or absent healing, all of which may cause late stent thrombosis. 4, 5 Axxion is developed using a degradable synthetic glycocalix, potentially resulting in less inflammation, less immunologic responses, and prevention of thrombosis. Our study, which was neither aimed nor powered to demonstrate the difference in stent thrombosis, showed a significant higher in-stent late loss and binary restenosis by the use of PF-PES.
Compared with ASPECT and ELUTES, DELIVER showed higher late loss and higher percentage of in-stent restenosis for PF-PES. It is of note that all PF-PES used in those early trials had similar strut thickness, proprietary coating technique, and drug dose. One possible explanation could be different higher lesion complexity and diabetic patients in DELIVER as compared with others. This is supported by the fact that our trial, which included the same rate of diabetic patients and lesion complexity as DELIVER, gave the same results. Increase in lesion complexity may indeed wipe off the drug from stent surface during stent delivering and deployment. Scanning electron microscopic analysis for DES after failed implantation in tortuous and calcified vessels has, for example, demonstrated that DES without polymer has more areas where the drug was wiped off stent surface as compared with DES with durable polymer. 28 A preclinical study of DELIVER has also estimated that ≈40% of drug is lost during stent delivery of PF-PES. 11 Cracking drug on stent surface may result in nonuniform local drug distribution with subsequent abnormal neointimal hyperplasia, as observed in DELIVER and in the present trial. The time course of neointimal proliferation in relation to in-stent restenosis in humans is not clearly known, but in a morphometric analysis of >40 human BMS collected at necropsy, peak neointimal thickness (0.78±0.37 mm) occurs between 6 months and 1 year, with ≈22% regression in neointimal growth after 1 year. 29 Therefore, drug release period (≈1 month) in Axxion could not be sufficient duration to suppress neointimal proliferation after stent implantation. Animal data showed that the amount of drug remaining on the stent was 72±7% at 4 hours, 53±10% at 4 days, and 31±13% at 14 days in ELUTES, 10 and drug release is relatively rapid and complete within days to weeks in DELIVER. 11 Because the drug is in direct contact with the tissue, uptake is determined by the rate at which the drug crosses the cell membrane. It is uncertain how drug diffusivities within Axxion could affect the artery wall, but various factors such as time course of drug elution, total amount of drug, and nonuniform drug release could affect tissue absorption. It is of note that Axxion differs from the PF-PES tested in previous trials for the fact that it has a glycocalix of 2 nm thickness, instead of a polymer. Although no pharmacokinetic data on paclitaxel elution are available for this particular combination, the presence of glycocalix should be taken into account when comparing Axxion with other PF-PES.
To completely eliminate the adverse effects related to the polymer, various attempts of direct application of drug to the stent surface without the use of polymers have been made. The Intracoronary Stenting and Angiographic Restenosis-Test Equivalence Between 2 Drug-Eluting Stents (ISAR-TEST) trial demonstrated no significant difference between the PF sirolimus-coated stent and the PB-PES in terms of antirestenotic effects at 6 to 8 months and clinical events at 5 years. 30, 31 The ISAR-TEST-2 demonstrated high antirestenotic efficacy of dual (sirolimus and probucol) DES equivalent to sirolimus-eluting stent (Cypher) in 6 to 8 months, and its efficacy equivalent to zotarolimus-eluting stent (Endeavor) remained durable between 1 and 2 years. 32, 33 Dual DES stent platform uses a thin-strut (87 μm), sand-blasted microporous, 316 L stainless steel stent backbone and is coated with a mixture of sirolimus, probucol, and shellac resin (a biocompatible resin widely used in the coating of medical tablets), which made it possible to release the drug >6 to 8 weeks. 34 Furthermore, a recent study showed that the PF-PES with a microporous surface, which increases the drug reservoir capacity and allows for a retarded drug release without obligatory application of a polymer, was equivalent to a biodegradable PB rapamycin-eluting stent in terms of 1-year major adverse cardiac event, including cardiac death, nonfatal myocardial infarction, and target lesion revascularization. 35 Data on new PF-DES will help us clarify whether polymer concerns are only related to its absence or they can be globalized to the -imus family. In this regard, a PF amphilius-eluting stent with abluminal reservoirs (Cre8 stent; CID, Saluggia, Italy) has a lower late loss compared with PB-PES with comparable clinical outcome at 1 year. 36 A reservoir system such as microporous and amphilius technology for carrying drugs can increase the amount of drug storage, control drug release, and promote endothelialization without increasing neointimal proliferation.
Data of our study emphasize the importance of polymer in guiding stent drug elution, because PF stents exhibited an extremely higher late loss and a higher rate of target lesion revascularization as compared with a PB stent delivering the same drug. These results should be, therefore, taken into account for future stent design, because polymer-free products are still in development. In light of our data, new drugs, whose elution from the stent platform is not much dependent on a polymer or reservoir technology, 12, 13, 36 could probably still represent 2 interesting fields of innovation in PF-DES development.
Limitations
Several limitations should be acknowledged. The study was prematurely discontinued because of higher-than-expected rate of events in the studied stent arm. The routine follow-up angiogram could have increased the incidence of TVR that may not reflect real-life practice. However, as mandated per protocol, all TVR performed during follow-up were ischemiadriven. Second, the PF-PES of this study is no longer available in the market. Therefore, results of this study will not be translated directly into clinical practice, but may represent important insights of PF-DES technology for manufacturing new-generation stents.
Conclusions
Compared with PB-PES, PF-PES was associated with increased neointimal proliferation and subsequent clinical restenosis. The polymer plays an essential role on the outcome after drug-eluting stent implantation.
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